Literature DB >> 33152068

Screening for functional transcriptional and splicing regulatory variants with GenIE.

Sarah E Cooper1,2, Jeremy Schwartzentruber1,2,3, Erica Bello1,2, Eve L Coomber1, Andrew R Bassett1,2.   

Abstract

Genome-wide association studies (GWAS) have identified numerous genetic loci underlying human diseases, but a fundamental challenge remains to accurately identify the underlying causal genes and variants. Here, we describe an arrayed CRISPR screening method, Genome engineering-based Interrogation of Enhancers (GenIE), which assesses the effects of defined alleles on transcription or splicing when introduced in their endogenous genomic locations. We use this sensitive assay to validate the activity of transcriptional enhancers and splice regulatory elements in human induced pluripotent stem cells (hiPSCs), and develop a software package (rgenie) to analyse the data. We screen the 99% credible set of Alzheimer's disease (AD) GWAS variants identified at the clusterin (CLU) locus to identify a subset of likely causal variants, and employ GenIE to understand the impact of specific mutations on splicing efficiency. We thus establish GenIE as an efficient tool to rapidly screen for the role of transcribed variants on gene expression.
© The Author(s) 2020. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Year:  2020        PMID: 33152068      PMCID: PMC7736817          DOI: 10.1093/nar/gkaa960

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  34 in total

1.  96-plex molecular barcoding for the Illumina Genome Analyzer.

Authors:  Iwanka Kozarewa; Daniel J Turner
Journal:  Methods Mol Biol       Date:  2011

2.  Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways.

Authors:  Aleksandra M Wojtas; Silvia S Kang; Benjamin M Olley; Maureen Gatherer; Mitsuru Shinohara; Patricia A Lozano; Chia-Chen Liu; Aishe Kurti; Kelsey E Baker; Dennis W Dickson; Mei Yue; Leonard Petrucelli; Guojun Bu; Roxana O Carare; John D Fryer
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-12       Impact factor: 11.205

3.  Nucleosomes impede Cas9 access to DNA in vivo and in vitro.

Authors:  Max A Horlbeck; Lea B Witkowsky; Benjamin Guglielmi; Joseph M Replogle; Luke A Gilbert; Jacqueline E Villalta; Sharon E Torigoe; Robert Tjian; Jonathan S Weissman
Journal:  Elife       Date:  2016-03-17       Impact factor: 8.140

4.  Mechanisms of precise genome editing using oligonucleotide donors.

Authors:  Yinan Kan; Brian Ruis; Taylor Takasugi; Eric A Hendrickson
Journal:  Genome Res       Date:  2017-03-29       Impact factor: 9.043

5.  CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome.

Authors:  Tyler S Klann; Joshua B Black; Malathi Chellappan; Alexias Safi; Lingyun Song; Isaac B Hilton; Gregory E Crawford; Timothy E Reddy; Charles A Gersbach
Journal:  Nat Biotechnol       Date:  2017-04-03       Impact factor: 54.908

6.  Clusterin Is Required for β-Amyloid Toxicity in Human iPSC-Derived Neurons.

Authors:  Jacqueline P Robbins; Leo Perfect; Elena M Ribe; Marcello Maresca; Adrià Dangla-Valls; Evangeline M Foster; Richard Killick; Paulina Nowosiad; Matthew J Reid; Lucia Dutan Polit; Alejo J Nevado; Daniel Ebner; Mohammad Bohlooly-Y; Noel Buckley; Menelas N Pangalos; Jack Price; Simon Lovestone
Journal:  Front Neurosci       Date:  2018-07-25       Impact factor: 4.677

7.  Simultaneous precise editing of multiple genes in human cells.

Authors:  Stephan Riesenberg; Manjusha Chintalapati; Dominik Macak; Philipp Kanis; Tomislav Maricic; Svante Pääbo
Journal:  Nucleic Acids Res       Date:  2019-11-04       Impact factor: 16.971

8.  RNA splicing is a primary link between genetic variation and disease.

Authors:  Yang I Li; Bryce van de Geijn; Anil Raj; David A Knowles; Allegra A Petti; David Golan; Yoav Gilad; Jonathan K Pritchard
Journal:  Science       Date:  2016-04-28       Impact factor: 47.728

9.  High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.

Authors:  Benjamin P Kleinstiver; Vikram Pattanayak; Michelle S Prew; Shengdar Q Tsai; Nhu T Nguyen; Zongli Zheng; J Keith Joung
Journal:  Nature       Date:  2016-01-06       Impact factor: 49.962

10.  Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage.

Authors:  Alexis C Komor; Yongjoo B Kim; Michael S Packer; John A Zuris; David R Liu
Journal:  Nature       Date:  2016-04-20       Impact factor: 49.962

View more
  5 in total

Review 1.  Deciphering pathogenicity of variants of uncertain significance with CRISPR-edited iPSCs.

Authors:  Hongchao Guo; Lichao Liu; Masataka Nishiga; Le Cong; Joseph C Wu
Journal:  Trends Genet       Date:  2021-09-08       Impact factor: 11.639

Review 2.  Integration of Transformative Platforms for the Discovery of Causative Genes in Cardiovascular Diseases.

Authors:  Haocheng Lu; Jifeng Zhang; Y Eugene Chen; Minerva T Garcia-Barrio
Journal:  Cardiovasc Drugs Ther       Date:  2021-04-15       Impact factor: 3.947

Review 3.  The application of genome-wide CRISPR-Cas9 screens to dissect the molecular mechanisms of toxins.

Authors:  Bei Wang; Jun-Zhu Chen; Xue-Qun Luo; Guo-Hui Wan; Yan-Lai Tang; Qiao-Ping Wang
Journal:  Comput Struct Biotechnol J       Date:  2022-09-13       Impact factor: 6.155

Review 4.  Advancing drug discovery using the power of the human genome.

Authors:  Karl Heilbron; Sahar V Mozaffari; Vladimir Vacic; Peng Yue; Wei Wang; Jingchunzi Shi; Adrian M Jubb; Steven J Pitts; Xin Wang
Journal:  J Pathol       Date:  2021-04-09       Impact factor: 7.996

Review 5.  CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer.

Authors:  Laia Castells-Roca; Eudald Tejero; Benjamín Rodríguez-Santiago; Jordi Surrallés
Journal:  Cancers (Basel)       Date:  2021-03-30       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.